课题基金 / 基金详情

A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL

A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL
评估 CTL 安全性和免疫原性的 I 期临床试验
批准号:
7731391
负责人:
PETER Edwin WRIGHT
金额:
$0.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-09-16

项目摘要

项目成果

PETER Edwin WRIGHT的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aims: To evaluate the safety and tolerability of intramuscular administrations of the HIV CTL MEP vaccine formulated with RC539-SE with and without GM-CSF
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural characterization of large eukaryotic proteins containing both folded and disordered domains
  • 批准号:
    10552345
  • 项目类别:
  • 资助金额:
    $45.25万
  • 财政年份:
    2023
  • 负责人:
    PETER Edwin WRIGHT
  • 依托单位:
Molecular mechanisms of transthyretin amyloidosis
  • 批准号:
    10115719
  • 项目类别:
  • 资助金额:
    $45.64万
  • 财政年份:
    2020
  • 负责人:
    PETER Edwin WRIGHT
  • 依托单位:
Molecular mechanisms of transthyretin amyloidosis
  • 批准号:
    10599188
  • 项目类别:
  • 资助金额:
    $46.54万
  • 财政年份:
    2020
  • 负责人:
    PETER Edwin WRIGHT
  • 依托单位:
Molecular mechanisms of transthyretin amyloidosis
  • 批准号:
    10372930
  • 项目类别:
  • 资助金额:
    $45.64万
  • 财政年份:
    2020
  • 负责人:
    PETER Edwin WRIGHT
  • 依托单位: